Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phloretin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.87 |
| ▸ | SLC5A1 | P13866 | 7/20 | 0.87 |
| ▸ | SLC5A2 | P31639 | 7/20 | 0.87 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.87 |
| ▸ | MAPT | P10636 | 3/20 | 0.87 |
| ▸ | GAA | P10253 | 2/20 | 0.87 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.87 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.87 |
| ▸ | RELA | Q04206 | 2/20 | 0.87 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.87 |
| ▸ | THRB | P10828 | 2/20 | 0.87 |
| ▸ | HPGD | P15428 | 2/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.87 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.87 |
| ▸ | LMNA | P02545 | 1/20 | 0.87 |
| ▸ | TTR | P02766 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phloretin SCHEMBL27910960 | 0.93 | SLC5A1 (0.93) | SLC5A1SLC5A2CYP19A1MAPTGAA | |
| Phloretin SCHEMBL1506325 | 0.93 | SLC5A1 (1.00) | SLC5A1SLC5A2CYP19A1MAPTGAA | |
| Phloretin SCHEMBL38131 | 0.93 | SLC5A1 (1.00) | SLC5A1SLC5A2CYP19A1MAPTGAA | |
| Phloretin SCHEMBL31684375 | 0.92 | SLC5A1 (0.96) | SLC5A1SLC5A2CYP19A1MAPTGAA | |
| Phloretin SCHEMBL30785809 | 0.92 | SLC5A1 (0.96) | SLC5A1SLC5A2CYP19A1MAPTGAA | |
| Phloretin SCHEMBL30912872 | 0.92 | SLC5A1 (0.96) | SLC5A1SLC5A2CYP19A1MAPTGAA | |
| Phloretin SCHEMBL28362318 | 0.90 | SLC5A1 (0.87) | SLC5A1SLC5A2CYP19A1MAPTGAA | |
| Phloretin SCHEMBL27817019 | 0.90 | SLC5A1 (0.87) | SLC5A1SLC5A2CYP19A1MAPTGAA | |
| Phloretin SCHEMBL21192491 | 0.87 | SLC5A1 (0.87) | SLC5A1SLC5A2CYP19A1MAPTGAA | |
| Phloretin SCHEMBL30603791 | 0.87 | SLC5A1 (0.87) | SLC5A1SLC5A2CYP19A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187195-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | PEERCE BRIAN E (US) | 2005-08-25 | — | — | US | disclosed |
| US-6787528-B2 | THERAPY FOR KIDNEY DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-09-07 | — | — | US | disclosed |
| US-20030162753-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-08-28 | — | — | US | disclosed |
| US-20020133036-A1 | Inhibitors of intestinal apical membrane Na/phosphate co-transportation | PEERCE BRIAN E (US) | 2002-09-19 | — | — | US | disclosed |
| US-6355823-B1 | MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-03-12 | — | — | US | disclosed |
| EP-1175425-A2 | INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000043402-A2 | INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187195-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | SLC34A3, SLC34A1, SLC34A2 | ESR1 2885/4885SLC5A1 73/4885SLC5A2 90/4885 |
| US-20020133036-A1 | Inhibitors of intestinal apical membrane Na/phosphate co-transportation | SLC10A2, SLC34A3, SLC34A1 | ESR1 3212/4885SLC5A1 80/4885SLC5A2 94/4885 |
| US-20030162753-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | SLC34A3, SLC34A1, SLC34A2 | ESR1 2885/4885SLC5A1 73/4885SLC5A2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.